177 results about "Cerebral damage" patented technology

The invention discloses a rehabilitation assisting method and device suitable for cognitive disorder treatment and a medium, and relates to medical rehabilitation. A tablet personal computer, a millimeter wave radar and the like are included, artificial intelligence technologies such as signal processing and deep learning are utilized, and rehabilitation training of patients with mild cognitive impairment caused by brain injury and cerebral apoplexy is assisted. Basic information, medical history and current cognitive conditions of the patient are recorded and collected through the tablet computer, and a rehabilitation file is generated; based on the cognitive disorder type and severity of the patient, a rehabilitation training plan is intelligently made; a patient performs rehabilitation training through a gamified training interface, and the physiological state in the training process is monitored in real time in a non-contact mode based on millimeter wave radar; a deep learning model is used for analyzing training data of the patient, and rehabilitation progress is evaluated; training and evaluation data are summarized, and a subsequent rehabilitation scheme is optimized. Full-process automatic management from patient information collection, training plan making, training implementation, rehabilitation evaluation to data analysis report generation can be rapidly and accurately achieved, and the cognitive rehabilitation efficiency and effect are improved.

Compositions and methods for administering ketone bodies to a subject include beta-hydroxybutyrate complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The invention provides an individualized TMS target positioning method and system for spastic cerebral palsy children, and aims to realize TMS precise nerve regulation and control for different types of SCP children. According to the method, the structural features of the healthy child are obtained, and after image processing, accurate division of the SCP child brain region is achieved, the defects of a current brain injury child brain region spectrogram are overcome, and a basis is provided for seed point selection of different SCP symptoms; multi-modal image parameter features are further scanned, whole-brain voxel correlation analysis is performed based on seed points to construct functional connection diagrams, the crossed and overlapped functional connection diagrams are searched to serve as a liability focus network of different symptoms, a voxel set close to the scalp surface serves as a TMS target, and SCP child treatment targets of different clinical symptoms are accurately positioned. Based on a focus network mapping technology, functional connection characteristics related to different symptoms or symptom complexes are better positioned, a specific brain network is identified, and an accurate intervention target is provided for TMS treatment.

The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal nose-to-brain administration. The effect of intranasal NAC nose-to-brain administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal nose-to-brain NAC can be used to treat a condition, for example, a brain injury.

The invention relates to the technical field of intracranial pressure monitoring, in particular to a craniocerebral injury patient secondary brain injury early warning method based on multi-modal fusion, which comprises the following steps: acquiring intracranial pressure, cerebral blood flow, electroencephalogram signals and brain tissue oxygen partial pressure signals, carrying out denoising and normalization processing, constructing a multi-modal normalized time sequence data set, and carrying out multi-modal fusion on the basis of the multi-modal normalized time sequence data set; and inputting a linear discriminant analysis model to generate a time sequence difference vector, constructing a difference driving map based on a Bayesian dynamic network model, identifying abrupt change nodes, outputting a risk early warning section set, and carrying out trend stability analysis and reconstruction optimization. According to the method, the abnormal state recognition sensitivity is improved through normalized processing of multi-modal signals, enhancement of signal fusion capability, quantitative capture of direction change, reconstruction of spatial relationship between signals, modeling of dynamic transition probability, recognition of abrupt change nodes, combination of time difference vector change, evaluation of signal linkage trend, positioning of risk sections and extraction of parameter features; and the early warning and intervention precision is improved.

The present invention relates generally to compositions and methods useful for treating brain injuries such as stroke, optic neuropathy, traumatic brain injury, and cerebral palsy. The methods comprise administering to a subject HMC obtained by in vitro differentiation of pluripotent stem cells and / or extracellular vesicles (EV) derived from these HMCs (HMC-EV).

The invention provides a response liposome for treating traumatic brain injury by targeting a blood-brain barrier loaded drug and a preparation method of the response liposome, and belongs to the field of traumatic brain injury treatment.The response liposome is prepared by preparing TfR-T12 target peptide firstly, then preparing nano-particles with hydrophobic molecular drugs wrapped inside, and finally preparing the TfR-T12 target peptide with the hydrophobic molecular drugs wrapped inside. And finally, preparing the response liposome for treating traumatic brain injury by the targeted blood-brain barrier loaded medicine. According to the application, the TfR-T12 target peptide which is highly expressed in cerebral cortex microvessels and can help a nano-drug to pass through a blood brain barrier through endocytosis is prepared as a target spot, meanwhile, the liposome is subjected to polypeptide modification, and the self-assembly driving force of the nano-particles is improved through process control; the outer surface of the response lipidosome is a target peptide, and the response lipidosome is internally coated with a nano-drug; the liposome can repair the blood brain barrier after injury, improve the blood flow of the brain, improve the drainage of the colloidal lymphatic system, improve the motor and cognitive functions of mice after injury, and reduce the dosage of drugs and various possible side effects caused by the drug dosage.

This disclosure describes methods and systems for preventing, moderating, and / or treating brain injury. The methods herein may include obtaining a test result reflecting a condition of a brain in the subject, determining a stimulation parameter based on the test result, and stimulating a nerve based on the stimulation parameter, wherein stimulation of the nerve assists or causes contraction of a respiratory muscle in the subject. The systems herein may include a processor configured to: receive a test result reflecting a condition of a brain in a subject, and determine a stimulation parameter based on the test result; and a stimulator configured to stimulate a nerve based on the stimulation parameter, wherein stimulation of the nerve assists or causes contraction of a respiratory muscle in the subject.

The present invention generally relates to compositions and methods useful for treating a brain injury such as stroke, optic neuropathy, traumatic brain injury, and cerebral palsy. The methods include administering HMCs obtained by in vitro differentiation of pluripotent stem cells and / or extracellular vesicles (EVs) derived from such HMCs (HMC-EVs) into a subject.

The invention relates to the technical field of medical equipment, in particular to an intermittent high-oxygen system. The intermittent hyperoxia system provided by the invention can monitor the oxygen concentration, temperature, humidity, pressure and other environmental parameters in the hyperoxia cabin in real time, has alarm and automatic correction functions, can ensure the safety in the hyperoxia treatment process, and avoids the harm to a testee due to the fact that the parameters exceed a set range. The intermittent hyperoxia system can be used for intermittent hyperoxia intervention in the acute stage of ischemic brain injury and other types of brain injury, can effectively improve the neurological function and reduce the cerebral infarction volume, and has important application value and market prospect.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control, and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

The invention relates to the technical field of fruit and vegetable fermented food processing, in particular to roxburgh rose and gastrodia elata preserved fruit fermentation liquor and a preparation method and application thereof.The roxburgh rose and gastrodia elata serve as main raw materials, the gastrodia elata is washed and diced, the roxburgh rose is sliced, seeds are removed, then mixing is conducted, curing and sugaring are conducted, and roxburgh rose and gastrodia elata preserved fruits are prepared and then transferred into a fermentation container to be fermented; according to the present invention, with the preparation process, the effective components of the rosa roxburghii tratt and the gastrodia elata are maintained to the maximum extent, and the rosa roxburghii tratt and the gastrodia elata are subjected to compatibility use in the manner so as to achieve the effect of the preserved fruit; the traditional Chinese medicine composition can play a role in improving mouse insomnia caused by PCPA from the aspects of improving sedative hypnotic and antioxidant capacities, reducing the inflammatory factor level, improving brain injury and the like, and '1 + 1gt; compared with artificially synthesized chemical drugs, the rosa roxburghii tratt and gastrodia elata functional sleep-aiding product has obvious advantages, has wide application value in the field of large health and health-care products, and also provides a certain new way for development of rosa roxburghii tratt and gastrodia elata functional sleep-aiding products.

The present inventive concept provides methods of determining whether a subject has cortical or cerebral visual impairment (CVI) as well as determining whether the subject has a traumatic brain injury thereby allowing treatment for these conditions. The present inventive concept also provides a standardized method for assessing pediatric or adolescent visual acuity.

The invention discloses application of selazinomethyl ether and a pharmaceutical composition thereof in preparation of a medicine for preventing or treating brain injury. The invention provides the application of selazine methyl ether in preparing the medicine for preventing or treating the brain injury for the first time, and selazine methyl ether has a remarkable effect in preventing or treating the brain injury, especially cerebral arterial thrombosis and the brain injury caused by hemorrhagic transformation of the cerebral arterial thrombosis. And cerebral injury caused by cerebral arterial thrombosis and hemorrhagic transformation can be obviously relieved. According to the application disclosed by the invention, the sefoazinomethyl ether has the effects of remarkably reducing the cerebral infarction area and behavioral scoring under the condition of middle cerebral artery occlusion; the selobezine methyl ether has the effects of remarkably reducing the hemorrhage area, hemorrhage score and behavioral score under acute high glucose and middle cerebral artery occlusion; the pharmaceutical composition containing selazine methyl ether can become a novel drug for preventing or treating brain injury, and can be used for treating various cerebrovascular diseases including cerebral arterial thrombosis and hemorrhagic transformation of cerebral arterial thrombosis.

The invention pertains to a new computer-implemented method for processing an EEG signal, that makes it possible to extract information about cerebral damage in full-term babies, born in asphyxia context, for help in an indication for treatment of hypoxic-ischemic encephalopathy (HIE), by computing a power spectral density (PSD) of an EEG signal, transforming the PSD by a mathematical function, processing the transformed values by data binning, and creating a probability distribution of the durations of the binned values.

The invention belongs to the technical field of medical treatment, and discloses application of dehydroequol to treatment of neonatal hypoxic ischemic encephalopathy. The dehydroequol is used for treating the neonatal hypoxic-ischemic encephalopathy, and it is proved that the dehydroequol can reduce the area of cerebral infarction induced by hypoxia and ischemia, relieve encephaledema and inhibit oxidative stress and copper death, and has a treatment effect on neonatal hypoxic-ischemic brain injury. Dehydroequol is a medicine for treating hypoxic ischemic encephalopathy of newborns and has a development prospect.

The invention is applicable to the field of brain-computer interfaces and rehabilitation medicine, and provides a brain injury function training device based on a brain-computer interface, which comprises a support frame, an electroencephalogram acquisition module, a signal processing module, a training control module, a feedback module, an evaluation module and a user interaction module, in the first stage, accurate collection and preprocessing of electroencephalogram signals are achieved through a flexible electrode array and a low-noise amplification and self-adaptive noise reduction technology; secondly, through linkage of an evaluation module and a training control module, dynamic optimization of a personalized training scheme is achieved; thirdly, constructing a visual, auditory and tactile multi-mode feedback and quantitative evaluation closed loop; according to the brain injury function training device, the problems that an existing device is low in electroencephalogram signal collection precision, fixed in training scheme and lack of a training-evaluation-adjustment closed loop are solved, the accuracy, adaptability and user participation degree of brain injury function training are improved, and the brain injury function training device is suitable for function recovery training of movement, cognition, language and the like of brain injury patients with cerebral apoplexy, cerebral trauma and the like.

The invention discloses an application of N6022 in improving brain injury after cardiac arrest resuscitation, and particularly relates to an application of N6022 or a derivative thereof given through a nose in improving the brain injury after cardiac arrest resuscitation and increasing the survival rate after cardiac arrest resuscitation. Compared with the prior art, the application has the advantages that the increased GSNOR enzyme activity of brain tissues after sudden cardiac arrest resuscitation can be effectively inhibited by nasal injection of N6022 into a sudden cardiac arrest resuscitation rat model; the N6022 can effectively improve the neurological function after cardiac arrest resuscitation and increase the survival rate after cardio-pulmonary resuscitation; n6022 is used for inhibiting the activity of GSNOR, so that the number of survival neurons of brain tissues after sudden cardiac arrest resuscitation can be increased; the delivery mode of the N6022 through the nose can effectively enable the N6022 to enter the brain tissue of the rat. According to the invention, a new application field of N6022 is developed, and a meaningful reference is provided for improving the cerebral function after sudden cardiac arrest resuscitation.

A multimodal optical imaging platform is used to obtain cerebral perfusion-metabolism mismatch metrics for rapid assessment of acute brain injury, ongoing (real-time) feedback to optimize cardiopulmonary resuscitation to improve neurological outcome, and rapid prognosis of recovery. Light of several wavelengths and types is delivered to the tissue, which is then absorbed and scattered by tissue components such as blood and cellular components. Some of this light scatters back to the surface, where it is captured by a detector. The resulting data are processed to obtain blood flow and oxygenation parameters, as well as tissue scattering. These parameters are then combined to calculate metabolism and flow-metabolism coupling / decoupling metrics, which are used to determine ischemic damage, ongoing need for optimal blood flow and oxygenation, and to predict cerebral recovery in patients with acute brain injury during and immediately after cardiac arrest, stroke, traumatic brain injury, etc.

The present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable vehicle and non-pungent derivatives of capsaicin, in their tautomeric forms and pharmaceutically acceptable salts, as the sole active ingredient, for use in the stimulation of the sphenopalatine ganglion and the enhancement of cerebral blood flow, to prevent or reduce brain injury resulting from decreased cerebral blood flow. The composition is administered via the oral transmucosal route, preferably in the form of a mucoadhesive tablet, and may be formulated for immediate or prolonged release, ensuring effective and tolerable absorption while avoiding the irritant effects associated with pungent capsaicin.

Disclosed are therapeutic methods comprising the delivery of particular substituted pyridine based compounds for lowering intracranial pressure (ICP) and / or lowering neurogenic inflammation in treating substance P mediated pathways in the brain such as, but not limited to concussion, post-concussive (or post-concussion) syndrome (PCS), traumatic brain injury (TBI) and stroke.

The present invention discloses the use of cytisine-N-methylene-(5,7,4'-trihydroxy) isoflavone in the preparation of a drug for treating cerebral infarction. The invention relates to the fields of medicine, natural products, traditional Chinese medicine, and functional foods. The compound has both alkaloid and isoflavone structures, a novel structure, and good drugability. It also contains both flavonoid and alkaloid structural characteristics and is combined with any excipient or carrier acceptable in pharmaceutical, nutritional, and food science. The compound of the present invention can be used as an active ingredient in the treatment of cerebral infarction, inhibiting ischemic brain damage. It not only has a significant therapeutic effect on cerebral infarction, but also possesses multi-level, multi-target comprehensive pharmacological effects and targeted treatment of various pathological mechanisms.

The present invention relates to a female neuroendoscope sleeve assembly for deep ventricles, comprising a primary sleeve, a primary sleeve core, a secondary sleeve, and a secondary sleeve core. The primary sleeve and the secondary sleeve can be nested with each other to construct a primary channel, and the secondary sleeve and the secondary sleeve core can be nested with each other and inserted into the primary sleeve to construct a secondary channel. Through the orderly coordination of the various components in the assembly, the replacement between a primary sleeve with a larger diameter and a shorter tube length for shallow brain tissue surgery and a secondary sleeve with a smaller diameter and a longer tube length for deep brain tissue surgery can be completed through coaxial exchange technology. The use of a thinner, more mobile, less brain-damaging, and more accurately positioned secondary sub-tube to enter deep tissue or ventricles is very beneficial to the protection of deep brain functional nuclei and numerous thin-walled arteries and veins in the ventricular wall, reducing surgical side effects, lowering surgical risks, and improving the patient's neurological function prognosis.

This invention relates to pharmaceutical compositions, including compositions adapted for intranasal administration, comprising an active ingredient, including dexmedetomidine, pomalidomide, a selective phosphodiesterase type 4 inhibitor such as roflumilast, or combinations thereof, useful in the treatment of traumatic brain injury (TBI), including to prevent or reduce the neurological sequalae of TBI.

A speckle contrast optical spectroscopy techniques for measuring cerebral blood metrics such as cerebral blood flow and / or cerebral blood volume at multiple regions of the brain using one or more light sources and detectors of a plurality of channels disposed on a headset worn by a subject and detecting a brain injury or other brain malfunction by comparing cerebral blood metrics measurement at different regions.

This invention relates to animal models and their applications, specifically to a method for constructing a spontaneous mouse cerebral edema model and its application. This invention utilizes PEN2... fl / + Mice and PEN2 fl / + Mice were mated to obtain PEN2. fl / fl Homozygous mice; then the obtained PEN2 fl / fl Mice and hGFAP Cre / + Mice were mated to obtain PEN2. fl / + hGFAP Cre / + Mice; the final PEN2 obtained fl / + hGFAP Cre / + Mice and PEN2 fl / fl Mice were mated to obtain PEN2. fl / fl hGFAP Cre / + The mouse model is a spontaneous mouse cerebral edema model. In this model, PEN2 protein levels are significantly downregulated, and the mouse exhibits a severe cerebral edema phenotype. This model can be used to establish a cerebral edema drug screening platform. It can also be used for research on cerebral edema-related diseases, such as the pathogenesis of cerebral edema caused by infection, glioma, and traumatic brain injury, as well as for the development of technologies and products for the diagnosis and treatment of related diseases.

The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis / prognosis / assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require ahead computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.

Described are methods and systems for transcervical access of the cerebral arterial vasculature and treatment of cerebral occlusions, including ischemic stroke. The methods and devices may include methods and devices which may provide aspiration and passive flow reversal, those which protect the cerebral penumbra during the procedure to minimize injury to brain, as well as distal catheters and devices to remove an occlusion. The methods and devices that provide passive flow reversal may also offer to the user a degree of flow control. Devices and methods which provide a way to securely close the access site in the carotid artery to avoid the potentially devastating consequences of a transcervical hematoma are also described.